Exchanging knowledge for wealth.

50/50: A Perfect Pilot Study from 3D Signatures on Blood-Based Prostate Cancer

3D Signatures Inc. just told the world that the results of a prospective blood-based prostate cancer pilot study using the Company’s proprietary TeloViewTM software platform was a perfect 50/50. Based on blinded blood samples, TeloViewTM correctly predicted the stability and aggressiveness of disease for each of the study’s 50 intermediate risk prostate cancer patients.…